These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 21627558

  • 1. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
    Karadag-Saygi E, Akyuz G, Bizargity P, Ay P.
    Gynecol Endocrinol; 2011 Dec; 27(12):1033-6. PubMed ID: 21627558
    [Abstract] [Full Text] [Related]

  • 2. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A.
    Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K.
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
    [Abstract] [Full Text] [Related]

  • 7. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
    D'Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescarmona GP, Isaia G.
    J Bone Miner Res; 2008 Mar; 23(3):373-9. PubMed ID: 17967134
    [Abstract] [Full Text] [Related]

  • 8. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
    Dundar U, Kavuncu V, Ciftci IH, Evcik D, Solak O, Cakir T.
    J Bone Miner Metab; 2009 Mar; 27(4):464-70. PubMed ID: 19301089
    [Abstract] [Full Text] [Related]

  • 9. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.
    Menopause; 2010 Mar; 17(1):140-4. PubMed ID: 19574937
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M, Tuzun C, Unlu Z, Tikiz C, Taneli F, Uyanik BS.
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
    Ilter E, Karalok H, Tufekci EC, Batur O.
    Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659
    [Abstract] [Full Text] [Related]

  • 12. Monitoring of Risedronate by biochemical bone markers in clinical practice.
    Bunyaratavej N.
    J Med Assoc Thai; 2005 Oct; 88(suppl 5):S34-6. PubMed ID: 17500121
    [Abstract] [Full Text] [Related]

  • 13. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 14. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K.
    J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
    [Abstract] [Full Text] [Related]

  • 15. Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy.
    Kumm J, Ivaska KK, Rohtla K, Vaananen K, Tamm A.
    Scand J Clin Lab Invest; 2008 Oct; 68(6):459-63. PubMed ID: 18609099
    [Abstract] [Full Text] [Related]

  • 16. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
    Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, Harsoulis F.
    Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
    [Abstract] [Full Text] [Related]

  • 17. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009 Jan; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S, Orio F, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanovà L, Colao A, Doldo P, Mastrantonio P, Zullo F.
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [Abstract] [Full Text] [Related]

  • 19. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A.
    Osteoporos Int; 2006 Sep; 17(5):693-703. PubMed ID: 16435076
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
    Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R.
    Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.